Teva Pharmaceutical Industries (TEVA) chief Shlomo Yanai predicts that his generics company can more than double its annual sales to $31 billion by 2015, making it eligible to be one of the top 10 “Big Pharma” companies. Wall Street analysts are mostly bullish on the stock and Moody’s last week boosted the company’s credit rating. [...]